Ultimovacs ASA (OSL:ULTI) 5-Year EBITDA Growth Rate : -15.30% (As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Ultimovacs ASA 5-Year EBITDA Growth Rate?

Ultimovacs ASA's EBITDA per Share for the three months ended in Dec. 2023 was kr-1.71.

During the past 3 years, the average EBITDA Per Share Growth Rate was -15.50% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was -15.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 9 years, the highest 3-Year average EBITDA Per Share Growth Rate of Ultimovacs ASA was -12.50% per year. The lowest was -23.60% per year. And the median was -15.50% per year.

Competitive Comparison of Ultimovacs ASA's 5-Year EBITDA Growth Rate

For the Biotechnology subindustry, Ultimovacs ASA's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ultimovacs ASA's 5-Year EBITDA Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ultimovacs ASA's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Ultimovacs ASA's 5-Year EBITDA Growth Rate falls into.

Ultimovacs ASA 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Ultimovacs ASA (OSL:ULTI) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

Ultimovacs ASA 5-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Ultimovacs ASA's 5-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Ultimovacs ASA (OSL:ULTI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ultimovacs ASA (OSL:ULTI) » Definitions » 5-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

ULTIo:Sweden 7UM:Germany

Address

Ullernchausseen 64, Oslo, NOR, 0379

Website

https://www.ultimovacs.com

Ultimovacs ASA is a pharmaceutical company involved in developing novel immunotherapies against cancer. Its product candidate is UV1, a peptide-based vaccine inducing T cell responses against the universal cancer antigen telomerase. The company and its proprietary technology are based on preclinical and clinical research on immunotherapies conducted at the Oslo University Hospital.